spacer
home > ict > autumn 2019 > software solutions
PUBLICATIONS
International Clinical Trials

Software Solutions






ICT: What are some of the marketplace trends for clinical trial management systems (CTMS)?

Ricky Lakhani: Historically, CTMS solutions have been rightly considered expensive, monolithic, and costly to both implement and maintain. Through improvements in technology, this has begun to change with Software-as-a- Service (SaaS) offerings. The continued growth and adoption of SaaS technology solutions, especially with a CTMS, will be a key industry trend in the coming years. This is true for smalland medium-sized companies striving to reduce the cost/ overhead of either home-grown or hosted solutions. Further to that, with the continued focus on data collection and analysis, companies are adopting CTMS solutions to eradicate the inefficiencies of spreadsheets and other manual tools. In regard to data collection, CTMS solutions are increasingly positioning themselves in the middle of an ecosystem of inbound and outbound data, reducing the amount of manual data entry and increasing the transparency of data for reporting and informed decision making.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Ricky Lakhani is a product management professional with more than a decade of global experience specialising in understanding customer requirements and developing products that are valuable, innovative, and successful in supporting pharmacovigilance and clinical operations for life science organisations. Ricky is responsible for managing the entire product lifecycle from product strategy, planning, and definition to development and delivery.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

PARIS & OXFORD, England & BOSTON--(BUSINESS WIRE)-- Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples. The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement